Trial Profile

Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO RESPIMAT vs. ICS-LABA Plus LAMA in Patients With COPD

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olodaterol/tiotropium bromide (Primary) ; Budesonide/formoterol/glycopyrrolate
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms AIRWISE
Sponsors Boehringer Ingelheim

Most Recent Events

19 Oct 2022 Results of post hoc subgroup analysis assessing whether triple therapy reduces the risk of M/S exacerbations only in a subset of COPD patients with an elevated blood EC , presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians
29 Jan 2021 Status changed from active, no longer recruiting to completed.
11 Sep 2020 Planned End Date changed from 30 Aug 2020 to 30 Sep 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com